Mietens C, Keinhorst H, Hilpert H, Gerber H, Amster H, Pahud J J
Eur J Pediatr. 1979;132(4):239-52. doi: 10.1007/BF00496847.
A milk immunoglobulin concentrate (MIC) containing antibodies to enteropathogenic E. coli strains was prepared by hyperimmunisation of pregnant cows and using the milk obtained during the first 6 to 8 days of lactation. The sterile concentrate contained 70 to 80% protein and 35 to 40% immunoglobulin. The antibacterial activity was measured by bacterial passive agglutination, bacteriostatic activity in vitro, phagocytic clearance in vivo, and a protection test in mice. Though differences in titers were observed, adequate immunologic activity was demonstrated by these tests. Clinical studies were performed with 60 patients (aged 10 days to 18 months) suffering from diarrhoea with isolation of enteropathogenic E. coli. They were treated for 10 days with MIC and stool cultures were done prior to, during, and 2, 3 and 4 days after termination of treatment. Among 51 patients infected with E. coli strains incorporated in the vaccine, stool cultures became negative in 43 (84.3%) after treatment with MIC and 8 remained positive. Nine patients infected with strains O 78:K80(B-) and O 114:K--(B-)--which were not included in the vaccine used for immunisation--served as controls. Only one patient in this group became negative. If all patients receiving antibiotics for non intestinal infections during the treatment period are omitted the results remained unaltered: MIC was effective in 32 out of 38 patients (84.2%). These differences were highly significant. These results provide evidence that treatment with specific MIC is effective in eliminating enteropathogenic E. coli from the intestine.
通过对怀孕母牛进行超免疫,并使用泌乳头6至8天期间获取的牛奶,制备了一种含有抗肠道致病性大肠杆菌菌株抗体的牛奶免疫球蛋白浓缩物(MIC)。无菌浓缩物含有70%至80%的蛋白质和35%至40%的免疫球蛋白。通过细菌被动凝集、体外抑菌活性、体内吞噬清除以及小鼠保护试验来测定抗菌活性。尽管观察到效价存在差异,但这些试验证明了足够的免疫活性。对60例(年龄在10天至18个月之间)患有腹泻且分离出肠道致病性大肠杆菌的患者进行了临床研究。他们用MIC治疗10天,并在治疗前、治疗期间以及治疗结束后2、3和4天进行粪便培养。在51例感染了疫苗中所含大肠杆菌菌株的患者中,用MIC治疗后43例(84.3%)的粪便培养结果转为阴性,8例仍为阳性。9例感染了O 78:K80(B-)和O 114:K--(B-)--(这两种菌株未包含在用于免疫的疫苗中)菌株的患者作为对照。该组中只有1例患者转为阴性。如果省略治疗期间所有因非肠道感染接受抗生素治疗的患者,结果不变:38例患者中有32例(84.2%)使用MIC有效。这些差异具有高度显著性。这些结果证明,用特异性MIC治疗可有效清除肠道中的肠道致病性大肠杆菌。